Ann: Pre-clinical Data Supports a Role for Veyonda in COVID-19, page-4

"...Associate Professor Michael Gantier, Head of the Nucleic Acids and Innate Immunity Laboratory at
Hudson Institute said: “TBK1 is a point of convergence of many inflammatory pathways, and a target
under significant investigation by several big pharmaceutical companies. Our latest findings, which are
being prepared for publication, demonstrate that idronoxil may have applications in a range of diseases
Noxopharm Limited. ABN 50 608 966 123
Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072 AUSTRALIA
where TBK1 facilitates aberrant inflammation. Critically, TBK1 also directly controls production of
interferon-beta, a cytokine associated with long-COVID symptoms.1 This suggests that idronoxil may not
only be useful to prevent progression of COVID-19 patients from mild to severe disease, but also may
decrease the risk of long-lasting post-infectious symptoms, seen in up to half of COVID-19 patients.”.

Got to go fire the chainsaws up to make an honest days pay but before leaving I re-read this release and I just realised the good professor from Hudson didn't use the term "veyonda' or "nox66" instead directly referencing idronoxil which came out of patent in 2015 from memory - also known as Phenoxodiol & NV-06. It occured to me that in various previous trials Phenoxodiol/Idronoxil/NV06 was well tolerated orally and through IV in various safety trials - question is why would the suppository route even be necessary? Novogen Mk 1 shareholders poured millions into the development of Phenoxodiol/Idronoxil/NV-06 - it was they who paid for it but around 2015 saw the patent over Idronoxil/Phenoxodiol/NV06 lapse. A mountain of material already exists into these older trials conducted by Novogen mk 1and its subsidiary - Marshall Edwards so why re-invent wheel?